SKLB-D1—a first-in-class selective inhibitor of ERK1/2 and ERK5—exhibits excellent tolerability and superior in vivo #AntiTumor efficacy and overcomes #DrugResistance via inducing mTOR/p70S6K and NCOA4-mediated #Ferritinophagy.
#STTT #OpenAccess: doi.org/10.1038/s413...
0
0
0
0